Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5396 and AZD8076 dMAbs in Healthy Adults
NCT05293249Phase 1Completed
- Start
- May 2022
- Primary completion
- Jun 2025
- Modality
- DNA Therapeutics, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD5396 and AZD8076 in coronavirus disease 2019 (COVID-19). Started May 2022; status: completed.
02
Drugs
AZD5396AZD8076
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05293249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293249.